Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome) Overview
Learn About Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
View Main Condition: Mucopolysaccharidoses (MPS)
Mucopolysaccharidosis type I (MPS I) is a condition that affects many parts of the body. This disorder was once divided into three separate syndromes: Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS I-H/S), and Scheie syndrome (MPS I-S), listed from most to least severe. Because there is so much overlap between each of these three syndromes, MPS I is currently divided into the severe and attenuated types.
Mutations in the IDUA gene cause MPS I. The IDUA gene provides instructions for producing an enzyme that is involved in the breakdown of large sugar molecules called glycosaminoglycans (GAGs). GAGs were originally called mucopolysaccharides, which is where this condition gets its name. Mutations in the IDUA gene reduce or completely eliminate the function of the IDUA enzyme. The lack of IDUA enzyme activity leads to the accumulation of GAGs within cells, specifically inside the lysosomes. Lysosomes are compartments in the cell that digest and recycle different types of molecules. Conditions that cause molecules to build up inside the lysosomes, including MPS I, are called lysosomal storage disorders. The accumulation of GAGs increases the size of the lysosomes, which is why many tissues and organs are enlarged in this disorder. Researchers believe that the GAGs may also interfere with the functions of other proteins inside the lysosomes and disrupt the movement of molecules inside the cell.
Severe MPS I occurs in approximately 1 in 100,000 newborns. Attenuated MPS I is less common and occurs in about 1 in 500,000 newborns.
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Ping Wang is a Physiatrist in Naperville, Illinois. Dr. Wang and is rated as an Advanced provider by MediFind in the treatment of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). Her top areas of expertise are Nontuberculous Mycobacterial Lung Disease, Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome), Kienbock's Disease, Endoscopy, and Islet Cell Transplantation.
Advocate Health And Hospitals Corporation
Michael Earing is a Pediatric Cardiologist and a Cardiologist in Oak Lawn, Illinois. Dr. Earing and is rated as an Advanced provider by MediFind in the treatment of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). His top areas of expertise are Congenital Heart Disease (CHD), Tetralogy of Fallot, Arachnodactyly, Marfan Syndrome, and Heart Transplant. Dr. Earing is currently accepting new patients.
Peter Bell is an Internal Medicine provider in Chicago, Illinois. Dr. Bell and is rated as an Advanced provider by MediFind in the treatment of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). His top areas of expertise are Ornithine Transcarbamylase Deficiency, Urea Cycle Disorders (UCD), Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome), Mucopolysaccharidoses (MPS), and Liver Transplant.
Summary: A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
Summary: A multi-center randomized clinical trial to compare OTL-203 (gene therapy) with stem cell transplant (standard of care) in patients with MPS-IH (Hurler syndrome).
Published Date: December 01, 2012
Published By: National Institutes of Health